Roivant Sciences Ltd (ROIV)
11.22
-0.18
(-1.62%)
USD |
NASDAQ |
May 17, 16:00
11.22
0.00 (0.00%)
After-Hours: 20:00
Roivant Sciences Total Liabilities (Quarterly): 728.10M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 728.10M |
| September 30, 2023 | 739.91M |
| June 30, 2023 | 802.51M |
| March 31, 2023 | 782.02M |
| December 31, 2022 | 775.82M |
| September 30, 2022 | 701.38M |
| Date | Value |
|---|---|
| June 30, 2022 | 822.52M |
| March 31, 2022 | 523.70M |
| December 31, 2021 | 529.62M |
| September 30, 2021 | 652.01M |
| June 30, 2021 | 474.86M |
| March 31, 2021 | 527.69M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
474.86M
Minimum
Jun 2021
822.52M
Maximum
Jun 2022
671.68M
Average
714.74M
Median
Total Liabilities (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 233.64M |
| Biodexa Pharmaceuticals Plc | 7.470M |
| Verona Pharma PLC | 64.92M |
| NuCana PLC | 16.46M |
| Autolus Therapeutics PLC | 263.91M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 7.313B |
| Shareholders Equity (Quarterly) | 6.090B |
| Debt to Equity Ratio | 0.0737 |
| Current Ratio | 27.79 |
| Net Debt Paydown Yield | -0.08% |